A novel oncogenic enhancer of estrogen receptor-positive breast cancer

Estrogen receptor-positive (ER(+)) breast cancer accounts for the majority of breast cancers diagnosed, and nearly 20% of patients do not respond to endocrine therapy. The pathogenesis of ER(+) breast cancer has not been well elucidated. The enhancer is a cis-regulatory element that promotes gene tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Chunjie, Duan, Jialun, Xie, Ying, Liu, Yixuan, Li, Peishan, Li, Jianwei, Zhao, Huihui, Guo, Haitao, Men, Yanchen, Ren, Yuxin, Xu, Jiarui, Wang, Guiling, Lu, Wanliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463563/
https://www.ncbi.nlm.nih.gov/pubmed/36159594
http://dx.doi.org/10.1016/j.omtn.2022.08.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463563/
https://www.ncbi.nlm.nih.gov/pubmed/36159594
http://dx.doi.org/10.1016/j.omtn.2022.08.029

Ejemplares similares